In March 2026, Organogenesis implemented a restructuring plan to align its operating structure with the prolonged recovery environment. The plan included a workforce reduction of 88 employees (approximately 10% of staff) and the closure of its St. Petersburg, Florida facility.

Expected impact: Expected to generate approximately $14 million in annualized cost savings, helping the company achieve positive adjusted EBITDA in the second half of 2026 and return to normalized profitability by Q4 2026.

Prioritizing the transition of pipeline candidates from HCT/P to BLA regulatory pathways to secure premium pricing, market exclusivity, and robust clinical backing. This is highlighted by the ReNu clinical development program for knee osteoarthritis.

Expected impact: Positions the company to capture share in the massive knee osteoarthritis market, targeting the Surgical and Sports Medicine (SSM) segment to constitute 30% of total revenue by 2027.

Expanding the company's footprint beyond chronic wound clinics into perioperative and SSM settings, leveraging placental-derived platforms like NuShield and Affinity, and rolling out the PuraPly XT line into complex surgical applications.

Expected impact: Aims to mitigate reimbursement pressures in the wound care space by diversifying revenue into the estimated $1.5 billion surgical market, targeting a segment growth rate that outpaces the industry average.